Research programme : tumour-infiltrating lymphocyte therapies - Turnstone Biologics
Latest Information Update: 01 Dec 2022
At a glance
- Originator Turnstone Biologics
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 29 Nov 2022 Turnstone Biologics signs CRADA with the NCI
- 06 Jul 2022 Turnstone Biologics expands the strategic alliance multi-year collaboration with Moffitt Cancer Center to advance next-generation tumour infiltrating lymphocyte therapies for Solid tumors
- 26 Apr 2022 Turnstone Biologics enters into collaboration agreement with University of Montreal for tumor-infiltrating lymphocyte